Form 4: ICU Medical Executive Daniel Woolson Reports Stock Transactions
SEC Form 4 Filing
Daniel Woolson, VP, GM-Infusion Capital at ICU Medical, reports the vesting and subsequent disposal of performance-based restricted stock units (PRSUs) and common stock.
Summary
- On March 15, 2025, Daniel Woolson, VP, GM-Infusion Capital at ICU Medical, reported transactions involving ICU Medical's common stock and performance-based restricted stock units (PRSUs).
- 2,923 PRSUs vested and were converted into common stock.
- Woolson disposed of 1,294 shares of common stock at a price of $143.45 per share to cover tax obligations.
- Following these transactions, Woolson directly owns 14,194 shares of common stock and 2,924 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine disclosure of insider transactions, and the sentiment is neutral.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they represent a small portion of the overall outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/17/2023 | Date the PRSUs were granted. |
| 03/15/2025 | Date of the reported transactions (vesting of PRSUs and disposal of common stock). |
| 03/15/2026 | Expiration date of the Performance Shares. |
| 03/17/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.